Gongwin Biopharm Holdings Co., Ltd. Statistics
Gongwin Biopharm Holdings Co., Ltd. (6617) Stock Statistics & Valuation Metrics
Total Valuation
Gongwin Biopharm Holdings Co., Ltd. has a market cap or net worth of TWD 15.11B. The enterprise value is TWD 6.38B.
- Market Cap
- TWD 15.11B
- Enterprise Value
- TWD 6.38B
Share Statistics
Gongwin Biopharm Holdings Co., Ltd. has 127,506,100 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 127,506,100
- Owned by Insiders
- ―
- Owned by Institutions
- 0.02%
Financial Efficiency
Gongwin Biopharm Holdings Co., Ltd.’s return on equity (ROE) is -0.05 and return on invested capital (ROIC) is -7.57%.
- Return on Equity (ROE)
- -0.05
- Return on Assets (ROA)
- -0.04
- Return on Invested Capital (ROIC)
- -7.57%
- Return on Capital Employed (ROCE)
- -0.08
- Revenue Per Employee
- 1.82M
- Profits Per Employee
- -5.71M
- Employee Count
- 20
- Asset Turnover
- 0.01
- Inventory Turnover
- 24.17
Valuation Ratios
The current PE Ratio of Gongwin Biopharm Holdings Co., Ltd. is -89.26. Gongwin Biopharm Holdings Co., Ltd.’s PEG ratio is 1.19.
- PE Ratio
- -89.26
- PS Ratio
- 345.66
- PB Ratio
- 6.27
- Price to FCF
- -69.94
- Price to Operating Cash Flow
- -70.96
- PEG Ratio
- 1.19
Income Statement
In the last 12 months, Gongwin Biopharm Holdings Co., Ltd. had revenue of 36.45M and earned -114.13M in profits. Earnings per share was -0.92.
- Revenue
- 36.45M
- Gross Profit
- 14.99M
- Operating Income
- -207.29M
- Pretax Income
- -120.87M
- Net Income
- -114.13M
- EBITDA
- -196.19M
- Earnings Per Share (EPS)
- -0.92
Cash Flow
In the last 12 months, operating cash flow was -205.67M and capital expenditures -3.00M, giving a free cash flow of -208.68M billion.
- Operating Cash Flow
- -205.67M
- Free Cash Flow
- -208.68M
- Free Cash Flow per Share
- -1.72
Dividends & Yields
Gongwin Biopharm Holdings Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1.45%
- Earnings Yield
- -1.15%
Stock Price Statistics
- Beta
- 0.77
- 52-Week Price Change
- 32.55%
- 50-Day Moving Average
- 123.77
- 200-Day Moving Average
- 89.59
- Relative Strength Index (RSI)
- 31.70
- Average Volume (3m)
- 827.33K
Important Dates
Gongwin Biopharm Holdings Co., Ltd. upcoming earnings date is ―, TBA (Confirmed).
- Last Earnings Date
- May 14, 2026
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
Gongwin Biopharm Holdings Co., Ltd. as a current ratio of 10.36, with Debt / Equity ratio of 5.13%
- Current Ratio
- 10.36
- Quick Ratio
- 10.35
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- 4.28
- Interest Coverage Ratio
- -40.17
Taxes
In the past 12 months, Gongwin Biopharm Holdings Co., Ltd. has paid 158.00K in taxes.
- Income Tax
- 158.00K
- Effective Tax Rate
- -0.00
Enterprise Valuation
Gongwin Biopharm Holdings Co., Ltd. EV to EBITDA ratio is -48.93, with an EV/FCF ratio of -65.83.
- EV to Sales
- 325.33
- EV to EBITDA
- -48.93
- EV to Free Cash Flow
- -65.83
- EV to Operating Cash Flow
- -66.79
Balance Sheet
Gongwin Biopharm Holdings Co., Ltd. has TWD 1.67B in cash and marketable securities with TWD 149.93M in debt, giving a net cash position of TWD 1.52B billion.
- Cash & Marketable Securities
- TWD 1.67B
- Total Debt
- TWD 149.93M
- Net Cash
- TWD 1.52B
- Net Cash Per Share
- TWD 11.93
- Tangible Book Value Per Share
- TWD 19.22
Margins
Gross margin is 23.43%, with operating margin of -573.78%, and net profit margin of -389.63%.
- Gross Margin
- 23.43%
- Operating Margin
- -573.78%
- Pretax Margin
- -417.11%
- Net Profit Margin
- -389.63%
- EBITDA Margin
- -664.90%
- EBIT Margin
- -691.32%
Analyst Forecast
The average price target for Gongwin Biopharm Holdings Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 11.66%
- EPS Growth Forecast
- -72.43%
